NCT03120364

Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over

A Randomized, Double Blinded, Multi-center Phase III Confirmatory Study to Assess the Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 824 (actual)
• Sponsor: SK Chemicals Co., Ltd. · Industry
• Sex: All
• Age: 50 Years
• Healthy volunteers: Accepted

Summary

This study assesses non-inferiority by comparing GMR(Geometric Mean Ratio) of NBP608 to Zostavax which are evaluated by gpELISA (Glycoprotein Enzyme Linked Immunosorbent Assay). Total of 824 healthy subjects (412 subjects per treatment arm) aged 50 and over are enrolled, and each subject is administered with single dose of vaccine which is randomly assigned.

Detailed description

This is a multi-center, randomized, double blinded, parallel-group study to assess the Immunogenicity and safety of NBP608 compared to Zostavax which are indicated for the prevention of herpes zoster. Total of 824 healthy subjects aged 50 and over are enrolled, and each subject is administered with single dose of vaccine which is randomly assigned in 1:1 ratio. Stratified randomization for age group is used to achieve the balance of treatment assignment within age strata. Total of five visits are scheduled including two visits via telephone contact. Blood sampling is conducted for immunogenicity assessment before and 6 weeks after vaccination at Visit 2 and Visit 4 respectively. Safety is monitored 1 week, 6 weeks and 26 weeks after vaccination through Visit 3\*, Visit 4 and Visit 5\* (\* telephone contact)

Conditions

• Herpes Zoster

Interventions

Type	Name	Description
BIOLOGICAL	NBP608	Preparation of Oka/SK strain of live, attenuated zoster virus
BIOLOGICAL	Zostavax	Preparation of Oka/Merck strain of live, attenuated zoster virus

Timeline

• Start date: 2015-09-09
• Primary completion: 2015-12-16
• Completion: 2016-04-28
• First posted: 2017-04-19
• Last updated: 2017-04-19

Locations

1 site across 1 country: South Korea